Improving protein therapeutics with sustained-release formulations

Nature Biotechnology

Volumn 16, Issue 2, 1998, Pages 153-

  Putney, Scott D ^a   Burke, Paul A ^b  

^a ALKERMES INC   (United States)

^b AMGEN INC   (United States)

Author keywords

Controlled release; Drug delivery; Microencapsulation; PLGA; Protein stability

Indexed keywords

ACETIC ACID ETHYL ESTER; ALPHA INTERFERON; BETA INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; DICHLOROMETHANE; ERYTHROPOIETIN; EXCIPIENT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; GROWTH HORMONE; HORMONE; HUMAN GROWTH HORMONE; INSULIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; LIPOSOME; MANNITOL; MICROSPHERE; MONOCLONAL ANTIBODY; NERVE GROWTH FACTOR; POLYMER; PROTEIN; RECEPTOR; SURFACTANT; TREHALOSE; UNINDEXED DRUG; UROKINASE; VASCULOTROPIN;

BIOAVAILABILITY; BIOTECHNOLOGY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; EMULSION; EVAPORATION; HUMAN; HYDROPHOBICITY; MICROENCAPSULATION; OXIDATION; PH; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; SOLID; SOLUTION AND SOLUBILITY; SUSTAINED RELEASE PREPARATION;

ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; PROTEINS;

EID: 2642677624     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0298-153     Document Type: Review

References (77)

1. Talmadge, J.E. 1993. The pharmaceutics and delivery of therapeutic polypeptides and proteins. Adv. Drug Del. Rev. 10:247-299.
2. Struck, M.M. 1994. Biopharmaceutical R&D success rates and development times:A new analysis provides benchmarks for the future, Bio/Technology 12:674-677.
3. Lee, H.J. 1995. Biopharmaceutical properties and pharmacokinetics of peptide and protein drugs. pp. 69-97 in Peptide-Based Drug Design. Taylor, M. and Amidon, G. (eds.), American Chemical Society, Washington, D.C.
4. Langer, R. 1990. New methods of drug delivery. Science 249:1527-1533.
5. Pitt, G.G. 1990. The controlled parenteral delivery of polypeptides and proteins. Int. J. Pharmaceuticals 59:173-196.
6. Cieland, J.L. and Jones, A.J.S. 1996. Stable formulations of recombinant human growth hormone and interferon gamma for microencapsulation in biodegradable polymers. Pharm. Res. 13:1462-1473.
7. Morlock, M., Kroll, H., Winter, G., and Kissel, T. 1997. Microencapsulation of merythropoietin using biodegradable poly(d,1-lactide-co-glycolide):protein stability and the effects of stabilizing exipients. Eur. J. Pharm. Biopharm. 43:29-36.
8. Krewson, C.E., Dause, R., Mak, M., and Saltzman, W.M. 1996. Stabilization of nerve growth factor in controlled release polymers and in tissue. J. Biomater. Sci. Polym. Ed. 8:103-117.
9. Mendez, A., Camarata, P.J., Suryanarayanan, R., and Ebner, T.J. 1997. Sustained intracerebral delivery of nerve growth factor with biodegradable polymer microspheres, Methods Neurosci. 21:150-167.
10. Cleland, J.L., Mac, A., Boyd, J., Yang, J., Duenas, E.T., Yeung, D., et al. 1997. The stability of recombinant human growth hormone in poly (lactic-co-glycolic acid) PLGA microspheres. Pharm. Res, 14:420-425.
11. Pettit, D.S., Pankey, S., Nightlinger, N., Disis, M., and Gombotz, W. 1996. GMCSF encapsulated in PLGA microspheres for vaccine adjuvancy. Proc. Intl. Symp. Control. Del. Bioact. Mater. 23:857-858.
12. Chen, L., Apte, R.N., and Cohen, S. 1997. Characterization of PLGA microspheres for the controlled delivery of IL-1 for tumor immunotherapy. J. Controlled Release 43:261-272.
13. Tabata, Y., Takebayashi, Y., Ueda, T., and Ikada, Y. 1993. A formulation method using D,L-lactic acid oligomer for protein release with reduced initial burst. J. Controlled Release 23:55-64.
14. Mittal, S.A., Cohen, A., Maysinger, D. 1994. In vitro effects of brain derived neurotropic factor released from microspheres. Neuroreport 5:2577-2582.
15. Zale, S.E., Burke, P.A., Bernstein, H.,and Brickner, A, 1996. Composition for sustained release of non-aggregated erythropoietin. U.S. Patent No. 5674534.
16. Cleland, J.L. and Duenas, E.T. 1997. Controlled delivery of nerve growth factor for local treatment of neuronal disease. Proc. Intl. Symp. Control. Del. Bioact. Mater. 24:323-824.
17. Tracy, M.A., Bernstein, H., and Kahn, M.A. 1996. Controlled release of metal-stabilized interferon. PTO Publication Number WO96/03116.
18. Johnson, O.L., Jaworowicz, W., Cleland, J.L., Bailey, L., Charnis, M., Duenas, E., et al. 1997. The stabilization and encapsulation of human growth hormone into biodegradable microspheres. Pharm. Res. 14:734-739.
19. Eppstein, D.A., Kurahara, C.G., Bruno, N.A., Van der Pas, M.A., Marsh, Y.V., and Schryver, B.B. 1986. Pathways to increasing efficacy of interferons:drug synergy and sustained release. pp. 401-409 in Biology of the interferon system. Stewart, W.E. and Schellekens, H. (eds.), Eisevier, New York.
20. Eppstein, D.A. and Schryver, B.B. 1990. Controlled release of macromolecular polypeptides. U.S. Patent 4962091.
21. Cleland, J.L., Duenas, E.T., Kahn, J. Park, A., Daugherty, A., and Cuthbertson, A. 1997. Local controlled delivery of vascular endothelial growth factor provides neovascularization. Proc. Intl. Symp. Control. Del. Bioact. Mater. 24:85-86.
22. Gombotz, W.R., Pankey, S.C., Bouchard, L.S., Ranchalis, J., and Puolakkainen, P. 1993. Controlled release of TGF-beta 1 from a biodegradable matrix for bone regeneration. J. Biomater. Sci. Polym, Ed. 5:49-63.
23. Hora, M.S., Rana, R.K., Nunberg, J.H., Tice, T.R., Gilley, R.M., and Hudson, M.E. 1990. Controlled release of interleukin-2 from biodegradable microspheres. Bio/Technology 8:755-758.
24. Ogawa, Y, Yamamoto, M., Okada, H., Yashiki, T., and Shimamoto, T. 1988. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid. Chem. Pharm. Bull. 5:1095-1103.
25. Sanders, L.M., Kell, B.A., McRae, G.I., and Whitehead, G.W. 1986. Prolonged controlled release of nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable polymeric implants:influence of composition and molecular weight of polymer. J. Pharm. Sci. 75:356-360.
26. Phillips, M.C. 1977. The conformation and properties of proteins at liquid interfaces. Chemistry and Industry 170-176.
27. Ter Beek, L.C., Ketelaars, M., McCain, D.C., Smulders, P.E.A., Walstra, P., and Hemminga, M.A. 1996. Nuclear magnetic resonance study of the confomation and dynamics of beta-casein at the oil/water interface in emulsions. Biophys. J. 70:2396-2402.
28. Maa, Y.-F. and Hsu, C. 1996. Liquid-liquid emulsification by rotor/stator homogenizatlon. J. Controlled Release 38:219-228.
29. Dickinson, E., Horne, D.S., Philipps, J.S., and Richardson, R.M. 1993. A neutron reflectivity study of the adsorption of beta-casein at fluid interfaces. Langmuir 9:242-248.
30. MacRitchie, F. 1978. Proteins at interfaces. Adv. Protein Chem. 32:283-311.
31. Lu, W. and Park, T.G. 1995. Protein release from poly (lactic-co-glycolic acid) microspheres:protein stability problems. Pharma. Sci. Technol. 49:13-19.
32. Dickinson, E. and Matsumura, Y. 1991. Time-dependent polymerization of beta-lactoblobulin through disulphide bonds at the oil-water interface in emulsions. Int. J. Biol. Macromol. 13:26-30.
33. Griebenow, K. and Klibanov, A.M. 1996. On protein denaturation in aqueous-organic mixtures but not in pure organic solvents. J. Amer. Chem. Soc. 118:11695-11700.
34. Singer, S.J. 1962. The properties of proteins in nonaqueous solvents. Adv. Prot. Chem. 17:1-68.
35. Arakawa, T. and Timasheff, S. 1985. The stabilization of proteins by osmolytes. Biophys. J. 47:411-414.
36. Pikal, M.J. 1996. Freeze drying of proteins. in Peptide and protein delivery, 2nd ed. Lee, V.H.L. (ed.), Marcel Dekker, New York.
37. Klibanov, A.M. 1989. Enzymatic catalysis in anhydrous organic solvents. Trends Biochem. Sci. 14:141-144.
38. Burke, P.A., Griffin, R.G., and Klibanov, A.M. 1992. Solid-state NMR assessment of enzyme active center structure under nonaqueous conditions. J. Biol. Chem. 267:20057-20064.
39. Desai, U.R. and Klibanov, A.M. 1995. Assesssing the structural integrity of a lyophilized protein in organic solvents. J. Am. Chem. Soc. 117:940-3945.
40. Gombotz, W., Healy, M., and Brown, L. 1991. Very low temperature casting of controlled release microspheres. U.S. Patent 5019400.
41. Johnson, O.L., Cleland, J.L., Lee, H.J., Charnis, M., Duenas, E., Jaworowicz, W., et al. 1996. A month-long effect from a single injection of microencapsulated human growth hormone. Nat. Med. 2:795-799.
42. Affleck, R., Xu, Z.-F., Suzawa, V., Focht, K., Ciark, D.S., and Dordick, J.S. 1992. Enzymatic catalysis and dynamics in low-water environments. Proc. Natl. Acad. Sci. USA 89:1100-1104.
43. Hageman, M. 1992. Water sorption and solid-state stability of proteins. pp. 273-309 in Stability of protein pharmaceuticals, part A; chemical and physical pathways of protein degradation. Ahern, T.J. and Manning, M.C. (eds.), Plenum Press, New York.
44. Pikal, M.J. 1994. Freeze-drylng of proteins:process, formulation and stability. pp. 120-133 in Formulation and delivery of proteins and peptldes. Cleland, J. and Langer, R. (eds.), American Chemical Society, Washington, D.C.
45. Vrkljan, M., Foster, T.M., Powers, M.E., Henkin, J., Porter, W.R., Staack, H., et al. 1994. Thermal stability of low molecular weight urokinase during heat treatment. II. Effect of polymeric additives. Pharm. Res. 11:1004-1008.
46. Gu, L.C., Erdos, E.A., Chiang, H.-S., Claderwood, T., Tsai, K., Visor, G.G., et al. 1991. Stability of interleukin 1b (IL-1b) in aqueous solution:analytical methods, kinetics, products, and solution formulation implications. Pharm. Res. 8:485-490.
47. Chang, B.S., Beauvais, R.M., Arakawa, T., Narhi, L.O., Dong, A.C., Aparisio, D.I., and Carpenter, J.F. 1996. Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solution. Biophys. J. 71:3399-3406.
48. Schroeder-Tefft, J.A., Bentz, H., and Estridge, T.D. 1997. Collagen and heparin matricies for growth-factor delivery. J. Controlled Release 48:29-33.
49. Chen, B., Arakawa, T., Morris, C.F., Kenney, W.C., Wells, C.M., and Pitt, C.G. 1994. Aggregation pathway of recombinant human keratinocyte growth factor and its stabilization. Pharm. Res. 11:1581-1587.
50. Tsai, P.K., Volkin, D.B., Dabora, J.M., Thompson, K.C., Bruner, M.W., Gress, J.O., et al. 1993. Formulation design of acidic fibroblast growth factor. Pharm. Res. 10:649-659.
51. Volkin, D.B., Tsai, P.K., Dabora, J.M., Gress, J.O., Burke, C.J., Linhanrdt, R.J., and Middaugh, C.R. 1993. Physical stabilization of acidic fibroblast growth factor by polyanions. Arch. Biochem. Biophys. 300:30-41.
52. Edelman, E.R., Mathiowitz, E., Langer, R., and Klagsbrun, M. 1991. Controlled and modulated release of basic fibroblast growth-factor. Biomaterials 12:619-626.
53. Burke, P.A. 1996. Determination of internal pH in PLGA microspheres using 31P NMR spectroscopy. Proceed. Intern. Symp. Control Rel. Bioact Mater. 23:133-134.
54. Liu, W.R., Langer, R., and Klibanov, A.M. 1991. Moisture induced aggregation of lyophilized proteins in the solid state. Biotechnol. Bioeng. 37:177-184.
55. Costantino, H.R., Langer, R., and Klibanov, A. 1994. Moisture-induced aggregation of lyophilized insulin. Pharm. Res. 11:21-29.
56. Wright, H.T. 1991. Nonenzymatic deamidation of asparaginyl and glutaminyl residues in proteins. Crit. Rev. Biochem. Mol. Biol. 26:1-52.
57. Li, S., Nguyen, T.H., Schoneich, C., and Borchardt, R.T. 1995. Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation. Biochemistry 34:5762-5772.
58. Coleman, J.E. 1992. Zinc proteins:enzymes, storage proteins, transcription factors, and replication proteins. pp. 897-946 in Annual reviews of biochemistry. Vol. 61. Richardson, C.C., Abelson, J.N., Meister, A., and Walsh, C.T. (eds.), Annual Reviews, Inc., Palo Alto, CA
59. Steiner, D.F., Bell, G.I., Tager, H.S., and Rubenstein, A.H. 1995. Chemistry and biosynthesis of the islet hormones:insulin, islet amyloid polypeptide (amylin), glucagon, somatostatin, and pancreatic polypeptide. pp. 1296-1328 in Endocrinology Vol. 2. DeGroot, L.J. (ed.), W.B. Saunders, Philadelphia.
60. Thorlacius-Ussing, O. 1987. Zinc in the anterior pituitary of the rat: a histochemical and analytical work. Neuroendocrinology 45:233-242.
61. Cunningham, B.C., Mulkerrin, M.G., and Wells, J.A. 1991. Dimerization of human growth hormone by zinc. Science 253:545-548.
62. Baldwin, R.L. 1996. How Hofmeister ion interactions affect protein stability. Biophys. J. 71:2056-2063.
63. Horbett, T. and Brash, J.L. 1986. Proteins at interfaces:current issues and future prospects. pp. 1-33 in Proteins at interfaces:physicochemical and biochemical Studies. Brash, J.L. and Horbett, T.A. (eds.), American Chemical Society, Washington, DC.
64. Boury.F, Marchais, H., Proust, J.E., and Benoit, J.P. 1997. Bovine serum albumin release from poly(alpha-hydroxy acid) microspheres:effects of polymer molecular weight and surface properties. J. Controlled Release 45:75-86.
65. Mathiowitz, E. and Langer, R. 1987. Polyanhydride microspheres as drug carriers. I. Hot-melt microencapsulation. J. Controlled Release 5:13-22.
66. Mathiowitz, E., Saltzman, W.M., Domb, A., Dor, P., and Langer, R. 1988. Polyanhydride microspheres as drug carriers. II. Microencapsulation by solvent removal. J. Appl. Polym. Sci. 35:755-774.
67. Heller, J., Sparer, R.V., and Zenter, G.M. 1990. Poly(ortho esters). pp. 121-161 in Biodegredable polymers as drug delivery systems. Chasin, M. and Langer, R. (eds.), Marcel Dekker. New York.
68. Zignani, M., Merkli, A., Sintzei, M.B., Bernatchez, S.F., Kloeti, W., Heller, J., et al. 1997. New generation of poly (ortho esters)-synthesis, characterization, kinetics, sterlization and biocompatibility. J. Controlled Release 48:115-129.
69. Creque, H.M., Langer, R., and Folkman, J. 1980. One month sustained release of insulin from a polymer implant. Diabetes 29:37-40.
70. Dinbergs, I.D., Brown, L. and Edelman, E.R. 1996. Cellular response to transforming growth factor-beta 1 and basic fibroblast growth factor depends on release kinetics and extracellular matrix interactions. J. Biol. Chem. 271:29822-29829.
71. Silberstein, G.B. and Daniel, C.W. 1987. Reversible inhibition of mammary gland growth by transforming growth factor-beta. Science 237:291-293.
72. Taniguchi, E., Nagae, Y., and Watanabe, H. 1991. The effect of recombinant epidermal growth factor in corneal angiogenesis. Nippon Ganka Gakkai Zasshi 95:52-55.
73. Mader, K., Nitschke, S., Strosser, R., and Borchert, H.H. 1997. Nondestructive and localized assessment of acidic microenvironments inside biodegradable polyanhyrides by spectral spatial electron-paramagnetic-resonance imaging. Polymer 38:4785-4794.
74. Leong, K.W., D'Amore, D.D., Marietta, M., and Langer, R. 1986. Bioerodible polyanhydrides as drug-carrier matricies. II. Biocompatibility and chemical reactivity. J. Biomed. Mater. Res. 20:51-64.
75. Arky, R. 1997. Physician's desk reference, Medical Economics Company, Montvale, NJ.
76. Harris, A.G., Kokoris, S.P., and Ezzat, S. 1995. Continuous vs. intermittent subcutaneous infusion of octreotide in the treatment of acromegaly. J. Clin. Pharmacol. 35:59-71.
77. Daughaday, W.F. 1995. Growth hormone, insulin-like growth factors and acromegaly. pp. 303-329 in Endocrinology Vol. 2. DeGroot, L.J. (ed.), W.B. Saunders and Co., Philadelphia.